Correlation between in vitro and in vivo behaviour of liposomal antigens.
Using conalbumin as a model antigen, we demonstrate in this paper that liposomal antigen differently influences the activation of the immune system depending on the mode of association of the antigen with the liposomal vehicle whether it is by encapsulation or surface linkage. This conclusion is based on in vivo data showing that encapsulated antigen induces a short-lasting response dominated by IgG1 production while surface-linked antigen has a longer-lasting effect characterized by increased production of IgM, IgG2a, IgG3 as well as of IgG1. The in vivo data were complemented by in vitro proliferation studies carried out on spleen cells or macrophage-depleted spleen cells obtained from mice sensitized in vivo and rechallenged in vitro on day 4 following sensitization. Rechallenge was carried out in the absence or presence of anti-IL1. The data indicate that, in contrast to what is generally observed in vivo, liposomes alone potentiate spleen cell proliferative response in a dose-dependent manner. This liposomal effect totally obscures the antigen-specific proliferation that was expected with encapsulated antigen without masking that induced by surface-linked antigen. The mode of antigen association also influences anti-cytokine responsiveness as demonstrated by the insensitivity of the surface-linked antigen response to the presence of anti-IL1 and the significantly decreased response observed with encapsulated antigen under identical conditions. The response to both liposomal antigenic formulations was almost totally abolished in adherent cell-depleted cultures. The overall results therefore suggest that encapsulated and surface-linked antigens activated different immune pathways.
Shahum
E
E
Département de Chimie-Biologie, Université du Québec à Trois-Rivières, Québec, Canada.
Thérien
H M
HM
D000276:Adjuvants, Immunologic; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology*; D002478:Cells, Cultured; D003207:Conalbumin / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D004337:Drug Carriers; D004339:Drug Compounding; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007075:Immunoglobulin M / Q000096:biosynthesis*; D008055:Lipids / Q000276:immunology; D008081:Liposomes; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008954:Models, Biological; D013154:Spleen / Q000166:cytology / Q000276:immunology; D014611:Vaccination
D000276:Adjuvants, Immunologic; D000954:Antigens, Surface; D004337:Drug Carriers; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008055:Lipids; D008081:Liposomes; D003207:Conalbumin